HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jmg.2006.044719v1 44/4/241    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antonio Casado, J. Articles by Bueren, J. A Search for Related Content PubMed PubMed Citation Articles by Antonio Casado, J. Articles by Bueren, J. A

A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network

¹ Spanish Fanconi Anemia Research Network and Centre for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain
² Department of Pediatric Oncology, Hematology and Immunology, Children’s Hospital, Düsseldorf, Germany
³ Department of Human Genetics, University of Wurzburg, Wurzburg, Germany

Correspondence to:
Dr J A Bueren
Hematopoiesis and Gene Therapy Program, CIEMAT Avenida Complutense, No 22, 28040 Madrid, Spain; juan.bueren{at}ciemat.es] Background: Fanconi anaemia is a heterogeneous genetic disease, where 12 complementation groups have been already described. Identifying the complementation group in patients with Fanconi anaemia constitutes a direct procedure to confirm the diagnosis of the disease and is required for the recruitment of these patients in gene therapy trials.

Objective: To determine the subtype of Fanconi anaemia patients in Spain, a Mediterranean country with a relatively high population (23%) of Fanconi anaemia patients belonging to the gypsy race.

Methods: Most patients could be subtyped by retroviral complementation approaches in peripheral blood T cells, although some mosaic patients were subtyped in cultured skin fibroblasts. Other approaches, mainly based on western blot analysis and generation of nuclear RAD51 and FANCJ foci, were required for the subtyping of a minor number of patients.

Results and conclusions: From a total of 125 patients included in the Registry of Fanconi Anaemia, samples from 102 patients were available for subtyping analyses. In 89 cases the subtype could be determined and in 8 cases exclusions of common complementation groups were made. Compared with other international studies, a skewed distribution of complementation groups was observed in Spain, where 80% of the families belonged to the Fanconi anaemia group A (FA-A) complementation group. The high proportion of gypsy patients, all of them FA-A, and the absence of patients with FA-C account for this characteristic distribution of complementation groups.

Abbreviations: DEB, diepoxybutane; FBS, fetal bovine serum; LCL, lymphoblast cell line; MMC, mitomycin C; PBS, phophate-buffered saline; TBS, TRIS-buffered saline

This article has been cited by other articles:

				J. A. Casado, P. Rio, E. Marco, V. Garcia-Hernandez, A. Domingo, L. Perez, J. C. Tercero, J. J. Vaquero, B. Albella, F. Gago, et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin Mol. Cancer Ther., May 1, 2008; 7(5): 1309 - 1318. [Abstract] [Full Text] [PDF]